ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: GlobeNewswire
$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated t
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year [Yahoo! Finance]Yahoo! Finance
- Earnings Call Insights: ARS Pharmaceuticals (SPRY) Q4 2024 [Seeking Alpha]Seeking Alpha
- ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $30.00 price target on the stock.MarketBeat
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 3/24/25 - Form SCHEDULE
- 3/21/25 - Form 4
- 3/20/25 - Form S-8
- SPRY's page on the SEC website